We look forward to bringing Europe our simple and effective all natural molluscum treatment that will allow parents to avoid expensive, painful, and other usually ineffective treatments.
Boise, Idaho (PRWEB) April 30, 2014
Naturopathix, Inc. plans to obtain a CE Mark to market and sell ZymaDerm™ throughout the 28 member countries in the European Union. ZymaDerm™ is the most widely used painless and inexpensive natural topical treatment for molluscum contagiosum In the United States.
The CE mark, which Naturopathix has applied for, will allow free movement and sale of ZymaDerm™ throughout the European Economic Area. CE marking is mandatory for certain product groups within the European Economic Area that includes most of Europe plus EFTA countries of Iceland, Norway, Switzerland, Liechtenstein, and Turkey. It certifies that Naturopathic conforms to its high standards.
“We look forward to bringing Europe our simple and effective all natural molluscum treatment that will allow parents to avoid expensive, painful, and other usually ineffective treatments,” says Briant Burke, MD, MS Briant, creator of ZymaDerm™ and Naturopathix’s medical director.
ZymaDerm™ is the most widely used painless and inexpensive natural treatment in the United States to rapidly make the unsightly molluscum skin bumps rapidly vanish, especially in children. Since its introduction in 2003, it has enabled over half a million people to quickly be rid of visible molluscum bumps caused by MCV.
The unsightly skin condition, that is highly contagious, is caused by the molluscum contagiosum virus. The lesions often rapidly spread and occur most often on the face, neck, armpit, arms, and trunk. However, it may occur anywhere on the body, except the palms of the hands and soles of the feet.
Molluscum contagiosum in children is more common than in adults. Children catch it when they come into contact with the virus, usually on the skin of another infected child or on a wet surface infected with the virus. It is a common infection throughout the world. In the US alone there are approximately 1- 2 million new cases each year.
"We feel we can serve a real need by helping to bring relief to people afflicted with this embarrassing condition,” continued Dr. Burke, “and rapidly alleviate the skin virus symptoms that include raised, unsightly, warty lesions or bumps on the skin.”
While the skin virus occurs primarily in young children, it is now becoming epidemic among adults. ZymaDerm™ is as effective for adults as well as children, and may be used safely on all body areas including the face and private areas.
Many leading dermatologists and pediatricians are replacing invasive and often painful treatments with this gentle, effective, natural treatment for their patients with molluscum contagiosum.
Results of an independent study of 346 physicians that used samples of ZymaDerm™ for their patients with molluscum contagiosum, showed that 92% of those responding rated it as effective, and 86% stated that they were either likely or extremely likely to use ZymaDerm™ as their preferred treatment method for molluscum contagiosum, compared to prescription drugs, over-the-counter treatment options, or physical destruction of lesions.
ZymaDerm™ is a patented blend of powerful all natural anti-viral plant-based compounds that transforms the treatment of molluscum contagiosum from expensive and often painful procedures, such as freezing, burning, or surgical removal of the lesions, to simply dabbing on a pleasant aromatic blend twice a day, usually for less than a month, until the lesions completely vanish. It is FDA approved as a homeopathic drug. Its ingredients are officially included in the Homeopathic Pharmacopeia of the United States as useful agents. The potency and level of purity of the ingredients in ZymaDerm™ meet the most stringent standards of excellence.
Naturopathix, Inc. was founded in 2002 to develop novel plant based therapeutic treatments for the relief of common medical conditions. The company is led by Dr. Briant Burke, a practicing physician and distinguished medical research scientist with over 20 years of clinical experience treating patients and publishing clinical trials.